AstraZeneca Stock: 3 Things to Know

Before you go, we thought you'd like these...
Before you go close icon

Shares of international drugmaker AstraZeneca have climbed more than 17% year to date, but a number of challenges lie ahead for the company. Despite bringing in a fresh management team last year and making acquisitions throughout 2013, it can take years to see tangible results in the pharmaceutical industry, and the turnaround at AstraZeneca is still unfolding.

In the following video, analyst Max Macaluso discusses the risks investors need to watch at AstraZeneca today, and focuses on three particular topics: revenue growth, its drug development pipeline, and acquisitions.

The Motley Fool's top stock of 2014
The market stormed out to huge gains across 2013, leaving investors on the sidelines burned. However, opportunistic investors can still find huge winners. The Motley Fool's chief investment officer has just hand-picked one such opportunity in our new report: "The Motley Fool's Top Stock for 2014." To find out which stock it is and read our in-depth report, simply click here. It's free!

The article AstraZeneca Stock: 3 Things to Know originally appeared on

Max Macaluso, Ph.D. has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading